Approval · Notice of Compliance 19690 · 2017
ADVIL HEADACHE CAPLETS: Notice of Compliance 19690
Issued August 22, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19690
- Date
- August 22, 2017
- Company
- Pfizer Consumer Healthcare, a division of Pfizer Canada ULCMississauga, Ontario, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ADVIL HEADACHE CAPLETS | 02467666 | Cancelled Pre Market |
| ADVIL HEADACHE EXTRA STRENGTH | 02467682 | Cancelled Pre Market |
| ADVIL HEADACHE TABLETS | 02467674 | Cancelled Pre Market |
Medicinal ingredients
- IBUPROFEN SODIUM DIHYDRATE 200 MG per TAB
- IBUPROFEN SODIUM DIHYDRATE 400 MG per TAB